EP0011426B1 - Halogen-substituted benzopyran- and benzothiopyran-4-carboxylic acids, their preparation and pharmaceutical compositions containing the same - Google Patents
Halogen-substituted benzopyran- and benzothiopyran-4-carboxylic acids, their preparation and pharmaceutical compositions containing the same Download PDFInfo
- Publication number
- EP0011426B1 EP0011426B1 EP79302467A EP79302467A EP0011426B1 EP 0011426 B1 EP0011426 B1 EP 0011426B1 EP 79302467 A EP79302467 A EP 79302467A EP 79302467 A EP79302467 A EP 79302467A EP 0011426 B1 EP0011426 B1 EP 0011426B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- chloro
- dihydro
- benzo
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Definitions
- This invention relates to novel halogen-substituted benzo[b]pyran- and benzo[b]thiopyran-4-carboxylic acids and derivatives thereof useful in the treatment of certain chronic complications arising from diabetes mellitus, such as diabetic cataracts and neuropathy und to pharmaceutical compositions containing such compounds.
- Such aldose reductase inhibitors function by inhibiting the activity of the enzyme reductase, which is primarily reponsible for regulating the reduction of aldoses, such as glucose and galactose to the corresponding polyols, such as sorbitol and galactitol, in humans and other animals.
- aldoses such as glucose and galactose
- polyols such as sorbitol and galactitol
- such compounds are of therapeutic value as aldose reductase inhibitors for controlling certain chronic diabetic complications, including those of an ocular nature, since it is known in the art that the presence of polyols in the lens of the eye leads to cataract formation, with a concommitant loss of lens clarity.
- the present invention relates to novel aldose reductase inhibitors useful as therapeutic agents for preventing or alleviating chronic diabetic complications.
- the compounds of the present invention are novel halogen substituted benzo[b]pyran- and benzo[b]thiopyran-4-carboxylic acids and derivatives thereof having the formula: and the pharmaceutically acceptable salts thereof, wherein
- R i is preferably chloro, fluoro or phenyl
- R is preferably hydrogen and preferred groups for R 2 and R 3 are hydrogen, methyl, chloro and, taken together, a fused benzene ring.
- Especially preferred compounds are those where n is zero, such as 6-chloro-8-methyl-3,4-dihydro-2H-1-benzo[b]pyran-4-carboxylic acid, 6,8-dichloro-3,4-dihydro-2H-1-benzo[b]pyran-4-carboxylic acid, 6-chloro-3,4-dihydro-2H-1-benzo[b]pyran-4-carboxylic acid, 6-chloro-3,4-dihydro-2H-naphtho[1,2-b]pyran-4-carboxylic acid, 6-phenyl-8-chloro-3,4-dihydro-2H-1-benzo[b]pyran-4-carboxylic acid and 6-fluoro-3,4-dihydro-2H-1-benzo[blpyran-4-carboxylic acid.
- a preferred compound when n is one is 6-chloro-3,4-dihydro-2H-benzo[b]pyran-4-acetic acid
- a further group of compounds of interest is that wherein X is sulphur.
- R 1 is chloro or fluoro
- R is hydrogen
- R 2 and R 3 are hydrogen, methyl or chloro.
- n is zero preferred compounds include 6,7-dichloro-3,4-dihydro-2H-1-benzo[b]thiopyran-4-carboxylic acid and 6-chloro-3,4-dihydro-2H-1-benzo[b]thiopyran-4-carboxylic acid.
- compositions comprising a pharmaceutically-acceptable carrier and a compound of Formula I in an amount effective to prevent or alleviate diabetes-associated complications, such as cataracts, neuropathy or retinopathy.
- the novel compounds of Formula I are readily prepared from the corresponding ketones of Formula II wherein R 1 , R z , R 3 and X are as previously defined.
- the ketone starting materials are commercially available or may be readily synthesized by reactions known in the art.
- the ketones may be prepared from an appropriately (R,, R 2 , R 3 )-substituted phenol or thiophenol by reaction with acrylonitrile in the presence of a strong base for example benzyltrimethylammonium hydroxide (Triton [Trade Mark] B), generally in excess acrylonitrile at reflux temperature.
- Triton [Trade Mark] B Triton [Trade Mark] B
- the resulting nitrile is hydrolyzed by heating with an acid such as hydrochloric acid, formic acid and the like, to form the corresponding 3-(R 1' R 2 , R 3 -substituted-phenoxy)-propionic acid, or the thio analog thereof.
- the acid may also be formed by the reaction of the (R" R Z , R 3 )-substituted phenol or thio-phenol with 3-bromo-propionic acid in the presence of a base, such as an alkali metal hydroxide, at a temperature of about 50 to 100°C.
- the ketone is formed by cyclization of the 3-(R,, R 2 , R 3 )-substituted-phenoxy)-propionic acid by heating in the presence of a strong acid such as polyphosphoric acid or sulfuric acid.
- n is zero are readily formed from the appropriately substituted ketone of Formula II by reaction with a trialkylsilyl cyanide to form the 4-cyano-4-trialkylsilyloxy- derivative, followed by reductive hydrolysis to the desired acid.
- a preferred trialkylsilyl cyanide for use in this reaction is trimethylsilyl cyanide, although other lower trialkylsilyl cyanides having from 1 to 4 carbon atoms in each alkyl group may be employed.
- the reaction of the ketone and the trialkylsilyl cyanide is conducted in the presence of a Lewis acid catalyst, such as a zinc halide, aluminum halide or boron trifluoride, with zinc iodide being a preferred catalyst.
- a Lewis acid catalyst such as a zinc halide, aluminum halide or boron trifluoride
- zinc iodide being a preferred catalyst.
- the reaction is generally conducted at temperatures in the range of about 0 to 50°C, preferably about 0 to 20°C, either neat or in an inert organic solvent, typically an ether such as diethyl ether, dimethoxyethane, tetrahydrofuran, dioxane and the like.
- the reaction is conducted in an inert atmosphere, for example under nitrogen.
- the 4-cyano-4-trialkylsilyloxy-derivative is then converted to the desired acid by heating with a stannous halide, such as stannous chloride dihydrate, in concentrated acid such as a mixture of glacial acetic acid and hydrochloric acid.
- a stannous halide such as stannous chloride dihydrate
- concentrated acid such as a mixture of glacial acetic acid and hydrochloric acid.
- the reaction is conducted at a temperature of about 100 to 200°C, preferably at reflux temperature, reaction generally being substantially complete in times of about 12 to 72 hours.
- the acids formed in the above described reaction are readily converted to the corresponding lower alkyl esters by conventional routes, for example by heating with the appropriate alkanol having from 1 to 4 carbon atoms in the presence of an acid catalyst, or by forming the corresponding acid chloride followed by reaction with the appropriate alcohol.
- n is one are prepared from the ketones of Formula II by the Wittig reaction with a trialkyl phosphonate ester, such as trimethyl phosphonoacetate, in the presence of a base, such as an alkali metal hydride, for example sodium hydride.
- a base such as an alkali metal hydride, for example sodium hydride.
- the reaction is generally conducted at about 0 to 50°C, preferably about 10 to 30°C, in a dry inert organic solvent such as tetrahydrofuran, dimethoxyethane, dioxane and the like.
- the olefinic ester produced by this reaction is then reduced, for example with hydrogen in the presence of a noble metal catalyst, preferably palladium on carbon.
- the reduction is conducted in an inert solvent such as ethyl acetate.
- an inert solvent such as ethyl acetate.
- the compound of Formula I where n is one is obtained as the corresponding alkyl ester, which can be converted to the acid by hydrolysis in the presence of a base, such as an alkali metal hydroxide, alkoxide or carbonate. If desired, the acid may be converted to esters having other R groups by conventional esterification methods.
- Compounds of Formula I wherein X is SO or S0 2 may be prepared from the corresponding compounds wherein X is sulfur by conventional oxidation methods.
- oxidation of compounds wherein X is sulfur with an alkali metal periodate, or with one equivalent of a peroxy acid results in compounds wherein X is SO.
- Oxidation with two equivalents of a peroxy acid may be employed to form those compounds wherein X is SO Z .
- the halogen substituent in at least one of the R 1 , R 2 or R 3 position is preferably present in the ketone starting material of Formula II.
- Other desired substituents for R,, R 2 and R 3 may likewise be introduced by reaction of the unsubstituted compounds using appropriate conventional reagents and methods.
- salts can be readily prepared from compounds of Formula I wherein R is hydrogen by conventional methods.
- these salts may be readily prepared by treating the halogen substituted benzopyran or benzothiopyran-4-carboxylic acids with an aqueous solution of the desired pharmaceutically acceptable cations, for example a solution of the hydroxide or carbonate, and evaporating the resulting solution to dryness, preferably under reduced pressure.
- a lower alkanol solution of the carboxylic acid of Formula I may be mixed with an alkoxide of the desired metal and the solution evaporated to dryness.
- Suitable pharmaceutically acceptable salts include, but are not limited to, those having potassium, sodium, ammonium, calcium, or magnesium as the cation.
- novel compounds of Formula I are useful as aldose reductase inhibitors and as such are of therapeutic value in the treatment of chronic complications of diabetes, such as cataracts, retinopathy and neuropathy.
- treatment is meant to include both prevention or alleviation of such conditions.
- the compounds may be administered to a subject in need of treatment by a variety of conventional routes of administration, including orally and parenterally. In general these compounds will be administered at dosages between 1 and 250 mg/kg body weight of the subject to be treated per day. However, some variation in dosage will necessarily occur depending on the condition of the subject being treated and the physician will, in any event, determine the appropriate dose for the individual subject.
- the compounds may be administered alone or in combination with pharmaceutically acceptable carriers, in either single or multiple doses.
- suitable pharmaceutically carriers include inert solid diluents, or fillers, sterile aqueous solutions and various non-toxic organic solvents.
- the pharmaceutical compositions formed by combining the novel benzopyran or benzothiopyran-4-carboxylic acids or derivatives thereof of Formula I and the pharmaceutically acceptable carrier are then readily administered in a variety of dosage forms such as tablets, powders, lozenges, syrups, in injectable solutions and the like.
- These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like.
- tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch and potato or tapioca starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
- lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes.
- Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules; preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols.
- the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerine and combinations thereof.
- solutions of the benzopyran- or benzothiopyran-4-carboxylic acid or derivatives thereof of Formula I in sesame or peanut oil or in aqueous propylene glycol may be employed, as well as sterile aqueous solution of the corresponding water-soluble alkaline metal or alkaline earth metal salts previously described.
- aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
- these particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal injection purposes.
- the sterile aqueous media employed are all readily obtainable by standard techniques well known to those skilled in the art.
- the activity of the compounds of the present invention as agents for the control of chronic diabetic complications may be determined by a number of standard biological or pharmacological tests. Suitable tests include (1) measuring their ability to inhibit the enzyme activity of isolated aldose reductase; (2) measuring their ability to reduce or inhibit sorbitol accumulation in the sciatic nerve of acutely streptozotocinized (i.e.
- diabetic rats (3) measuring their ability to reverse already-elevated sorbitol levels in the sciatic nerve and lens of chronic streptozotocin-induced diabetic rats; (4) measuring their ability to prevent or inhibit galactitol formation in the lens of acutely galactosemic rats; and (5) measuring their ability to delay cataract formation and reduce the severity of lens opacities in chronic galactosemic rats.
- reaction mixture was diluted with chloroform (500 ml), the organic layer washed 3 times with saturated sodium bicarbonate, and dried over magnesium sulfate. Filtration and removal of volatiles gave 6-phenyl-8-chloro-4-cyano-4-trimethylsilyloxy-3,4-dihydro-2H-1-benzo[b]pyran (5.5 g). Recrystallization from cyclohexane gave 1.5 g, of product, m.p. 99-100°C.
- 6-Chioro-3,4-dihydro-2H-1-benzo[b]thiopyran-4-one (6.8 g) was combined with trimethylsilyl cyanide (12 ml) and zinc iodide (0.30 g) and stirred at room temperature for 72 hours.
- the reaction mixture was diluted with diethyl ether, washed with saturated sodium bicarbonate and with saturated brine. After drying over magnesium sulfate the solution was filtered and evaporated to dryness under vacuum to give 6-chloro-4-cyano-4-trimethylsilyloxy-3,4-dihydro-2H-1-benzo[b]thiopyran (6.0 g, 57%) as an oil.
- trimethyl phosphonoacetate (10.9 g) was added dropwise to a slurry of 50% sodium hydride (2.9 g) in 300 ml freshly dried tetrahydrofuran and stirred at room temperature for 1 hour.
- a solution of 6-chloro-3,4-dihydro-2H-1-benzo[b]pyran-4-one (10 g) in 100 ml of freshly dried tetrahydrofuran was added dropwise, keeping the temperature below 30°C during the addition. The solution was then heated at reflux for 5 hours and stirred at room temperature for 12 hours.
- 6-Chloro-3,4-dihydro-2H-1-benzo[b]pyran-4-ylidene-acetic acid methyl ester (2.0 g) was reduced with hydrogen using a 10% Pd-charcoal catalyst (0.20 g) by stirring at 25°C in ethyl acetate for 4 hours.
- the reduction product, 6-chloro-3,4-dihydro-2H-1-benzo[b]pyran-4-acetic acid methyl ester (1.0 g) was heated for 3 days at reflux temperature with potassium hydroxide (2.4 g) in 25 ml water. The solution was acidified and extracted with chloroform.
- the compounds produced in Examples 2, 4, 6, 8, 10, 12, 14, 16 and 18 were tested for their ability to reduce or inhibit aldose reductase enzyme activity, following the procedure described in United States Patent No. 3,821,383 and based on the procedure of Hayman et. al., Journal of Biological Chemistry, 240, 877 (1965).
- the compounds of Examples 10, 12 and 14 were tested for their ability to reduce or inhibit sorbitol accumulation in the sciatic nerve of streptozotocinized (i.e., diabetic) rats by the procedure essentially described in United States Patent No. 3,821,383.
- the amount oi sorbitol accumulation in the sciatic nerves was measured 27 hours after induction of diabetes.
- the compounds were administered orally at a 25 mg/kg dosage level at 4, 8 and 24 hours following the administration of streptozotocin.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pyrane Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Description
- This invention relates to novel halogen-substituted benzo[b]pyran- and benzo[b]thiopyran-4-carboxylic acids and derivatives thereof useful in the treatment of certain chronic complications arising from diabetes mellitus, such as diabetic cataracts and neuropathy und to pharmaceutical compositions containing such compounds.
- In the past various attempts have been made to obtain new and more effective oral anti-diabetic agents. Generally, these efforts have involved synthesis of new organic compounds, particularly sulfonylureas, and determination of their ability to substantially lower blood sugar levels when administered orally. However, little is known about the effect of organic compounds in preventing or alleviating chronic complications of diabetes, such as diabetic cataracts, neuropathy and retinopathy. United States Patent No. 3,821,383 discloses aldose reductase inhibitors like 1,3-dioxo-lH- benz[d,e]isoquinoline-2[3H]-acetic acid and derivatives thereof stated to be useful for the treatment of these conditions. Such aldose reductase inhibitors function by inhibiting the activity of the enzyme reductase, which is primarily reponsible for regulating the reduction of aldoses, such as glucose and galactose to the corresponding polyols, such as sorbitol and galactitol, in humans and other animals. In this way, unwanted accumulations of galactitol in the lens of galactosemic subjects and of sorbitol in the lens, peripheral nervous cord and kidney of various diabetic subjects are prevented or reduced. Accordingly, such compounds are of therapeutic value as aldose reductase inhibitors for controlling certain chronic diabetic complications, including those of an ocular nature, since it is known in the art that the presence of polyols in the lens of the eye leads to cataract formation, with a concommitant loss of lens clarity.
- The present invention relates to novel aldose reductase inhibitors useful as therapeutic agents for preventing or alleviating chronic diabetic complications. Specifically, the compounds of the present invention are novel halogen substituted benzo[b]pyran- and benzo[b]thiopyran-4-carboxylic acids and derivatives thereof having the formula:
- X is selected from 0, S, SO, and S02;
- n is zero or one;
- R is selected from hydrogen and alkyl of 1 to 4 carbon atoms;
- R1 is selected from hydrogen, chloro, bromo, fluoro, and phenyl;
- RZ and R3, when taken individually are each selected from hydrogen, alkyl of 1 to 3 carbon atoms, chloro, bromo, and fluoro; and when taken together R2, R3 and the carbon atoms to which they are connected form a fused benzene ring; with the proviso that at least one of R1' R2 and R3 is selected from chloro, bromo and fluoro.
- One group of compounds of interest is that wherein X is oxygen. Ri is preferably chloro, fluoro or phenyl, R is preferably hydrogen and preferred groups for R2 and R3 are hydrogen, methyl, chloro and, taken together, a fused benzene ring. Especially preferred compounds are those where n is zero, such as 6-chloro-8-methyl-3,4-dihydro-2H-1-benzo[b]pyran-4-carboxylic acid, 6,8-dichloro-3,4-dihydro-2H-1-benzo[b]pyran-4-carboxylic acid, 6-chloro-3,4-dihydro-2H-1-benzo[b]pyran-4-carboxylic acid, 6-chloro-3,4-dihydro-2H-naphtho[1,2-b]pyran-4-carboxylic acid, 6-phenyl-8-chloro-3,4-dihydro-2H-1-benzo[b]pyran-4-carboxylic acid and 6-fluoro-3,4-dihydro-2H-1-benzo[blpyran-4-carboxylic acid. A preferred compound when n is one is 6-chloro-3,4-dihydro-2H-benzo[b]pyran-4-acetic acid.
- A further group of compounds of interest is that wherein X is sulphur. Preferably, R1 is chloro or fluoro, R is hydrogen, R2 and R3 are hydrogen, methyl or chloro. When n is zero preferred compounds include 6,7-dichloro-3,4-dihydro-2H-1-benzo[b]thiopyran-4-carboxylic acid and 6-chloro-3,4-dihydro-2H-1-benzo[b]thiopyran-4-carboxylic acid.
- Also embraced by the present invention are pharmaceutical compositions comprising a pharmaceutically-acceptable carrier and a compound of Formula I in an amount effective to prevent or alleviate diabetes-associated complications, such as cataracts, neuropathy or retinopathy.
- The novel compounds of Formula I are readily prepared from the corresponding ketones of Formula II
- Compounds of Formula I wherein n is zero are readily formed from the appropriately substituted ketone of Formula II by reaction with a trialkylsilyl cyanide to form the 4-cyano-4-trialkylsilyloxy- derivative, followed by reductive hydrolysis to the desired acid. A preferred trialkylsilyl cyanide for use in this reaction is trimethylsilyl cyanide, although other lower trialkylsilyl cyanides having from 1 to 4 carbon atoms in each alkyl group may be employed. The reaction of the ketone and the trialkylsilyl cyanide is conducted in the presence of a Lewis acid catalyst, such as a zinc halide, aluminum halide or boron trifluoride, with zinc iodide being a preferred catalyst. The reaction is generally conducted at temperatures in the range of about 0 to 50°C, preferably about 0 to 20°C, either neat or in an inert organic solvent, typically an ether such as diethyl ether, dimethoxyethane, tetrahydrofuran, dioxane and the like. Preferably, the reaction is conducted in an inert atmosphere, for example under nitrogen. The 4-cyano-4-trialkylsilyloxy-derivative is then converted to the desired acid by heating with a stannous halide, such as stannous chloride dihydrate, in concentrated acid such as a mixture of glacial acetic acid and hydrochloric acid. The reaction is conducted at a temperature of about 100 to 200°C, preferably at reflux temperature, reaction generally being substantially complete in times of about 12 to 72 hours. The acids formed in the above described reaction are readily converted to the corresponding lower alkyl esters by conventional routes, for example by heating with the appropriate alkanol having from 1 to 4 carbon atoms in the presence of an acid catalyst, or by forming the corresponding acid chloride followed by reaction with the appropriate alcohol.
- Compounds of Formula I wherein n is one are prepared from the ketones of Formula II by the Wittig reaction with a trialkyl phosphonate ester, such as trimethyl phosphonoacetate, in the presence of a base, such as an alkali metal hydride, for example sodium hydride. The reaction is generally conducted at about 0 to 50°C, preferably about 10 to 30°C, in a dry inert organic solvent such as tetrahydrofuran, dimethoxyethane, dioxane and the like. The olefinic ester produced by this reaction is then reduced, for example with hydrogen in the presence of a noble metal catalyst, preferably palladium on carbon. The reduction is conducted in an inert solvent such as ethyl acetate. The compound of Formula I where n is one is obtained as the corresponding alkyl ester, which can be converted to the acid by hydrolysis in the presence of a base, such as an alkali metal hydroxide, alkoxide or carbonate. If desired, the acid may be converted to esters having other R groups by conventional esterification methods.
- Compounds of Formula I wherein X is SO or S02 may be prepared from the corresponding compounds wherein X is sulfur by conventional oxidation methods. Thus, for example oxidation of compounds wherein X is sulfur with an alkali metal periodate, or with one equivalent of a peroxy acid results in compounds wherein X is SO. Oxidation with two equivalents of a peroxy acid may be employed to form those compounds wherein X is SOZ.
- In the above procedures, the halogen substituent in at least one of the R1, R2 or R3 position is preferably present in the ketone starting material of Formula II. However, it is also possible to introduce such substituents by reaction of the unsubstituted compounds of Formula I (l.e. where R1, R2 and R3 are hydrogen) using direct halogenation methods well known in the art. Other desired substituents for R,, R2 and R3 may likewise be introduced by reaction of the unsubstituted compounds using appropriate conventional reagents and methods.
- Pharmaceutically acceptable salts can be readily prepared from compounds of Formula I wherein R is hydrogen by conventional methods. Thus, these salts may be readily prepared by treating the halogen substituted benzopyran or benzothiopyran-4-carboxylic acids with an aqueous solution of the desired pharmaceutically acceptable cations, for example a solution of the hydroxide or carbonate, and evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, a lower alkanol solution of the carboxylic acid of Formula I may be mixed with an alkoxide of the desired metal and the solution evaporated to dryness. Suitable pharmaceutically acceptable salts include, but are not limited to, those having potassium, sodium, ammonium, calcium, or magnesium as the cation.
- The novel compounds of Formula I are useful as aldose reductase inhibitors and as such are of therapeutic value in the treatment of chronic complications of diabetes, such as cataracts, retinopathy and neuropathy. As used in the claims and specification hereof, treatment is meant to include both prevention or alleviation of such conditions. The compounds may be administered to a subject in need of treatment by a variety of conventional routes of administration, including orally and parenterally. In general these compounds will be administered at dosages between 1 and 250 mg/kg body weight of the subject to be treated per day. However, some variation in dosage will necessarily occur depending on the condition of the subject being treated and the physician will, in any event, determine the appropriate dose for the individual subject.
- The compounds may be administered alone or in combination with pharmaceutically acceptable carriers, in either single or multiple doses. Suitable pharmaceutically carriers include inert solid diluents, or fillers, sterile aqueous solutions and various non-toxic organic solvents. The pharmaceutical compositions formed by combining the novel benzopyran or benzothiopyran-4-carboxylic acids or derivatives thereof of Formula I and the pharmaceutically acceptable carrier are then readily administered in a variety of dosage forms such as tablets, powders, lozenges, syrups, in injectable solutions and the like. These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like. Thus, for oral administration, tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch and potato or tapioca starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules; preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration, the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerine and combinations thereof.
- For parenteral administration, solutions of the benzopyran- or benzothiopyran-4-carboxylic acid or derivatives thereof of Formula I in sesame or peanut oil or in aqueous propylene glycol may be employed, as well as sterile aqueous solution of the corresponding water-soluble alkaline metal or alkaline earth metal salts previously described. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal injection purposes. In this connection, the sterile aqueous media employed are all readily obtainable by standard techniques well known to those skilled in the art. Additionally, it is also possible to administer the compounds of Formula I topically by use of an appropriate opthalmic solution which may be administered dropwise to the eye.
- The activity of the compounds of the present invention as agents for the control of chronic diabetic complications may be determined by a number of standard biological or pharmacological tests. Suitable tests include (1) measuring their ability to inhibit the enzyme activity of isolated aldose reductase; (2) measuring their ability to reduce or inhibit sorbitol accumulation in the sciatic nerve of acutely streptozotocinized (i.e. diabetic) rats; (3) measuring their ability to reverse already-elevated sorbitol levels in the sciatic nerve and lens of chronic streptozotocin-induced diabetic rats; (4) measuring their ability to prevent or inhibit galactitol formation in the lens of acutely galactosemic rats; and (5) measuring their ability to delay cataract formation and reduce the severity of lens opacities in chronic galactosemic rats.
- The present invention and the preparation of certain starting materials is illustrated by the following examples.
- To a 500 ml single neck reaction flask equipped with a magnetic stirrer, a 250 ml pressure equalizing addition funnel, and a nitrogen inlet was added 6-phenyl-8-chloro-3,4-dihydro-2H-1-benzo[b]pyran-4-one (5.02 g) and anhydrous zinc iodide (0.50 g). The addition funnel was charged with trimethylsilyl cyanide (Sitar, 10 ml) and the reaction apparatus flushed with dry nitrogen. With vigorous stirring the trimethylsily cyanide was added over a 15 minutes period, causing a modest exotherm. The reaction mixture was stirred under nitrogen at room temperature for 48 hours. The reaction mixture was diluted with chloroform (500 ml), the organic layer washed 3 times with saturated sodium bicarbonate, and dried over magnesium sulfate. Filtration and removal of volatiles gave 6-phenyl-8-chloro-4-cyano-4-trimethylsilyloxy-3,4-dihydro-2H-1-benzo[b]pyran (5.5 g). Recrystallization from cyclohexane gave 1.5 g, of product, m.p. 99-100°C.
- To a 500 ml single neck reaction flask equipped with a magnetic stirrer, reflux condenser, and nitrogen inlet was added 6-phenyl-8-chloro-4-cyano-4-trimethylsilyloxy-3,4-dihydro-2H-1 - benzo[b]pyran (3.0 g). In one portion was added stannous chloride dihydrate (15 g) followed by glacial acetic acid (20 ml) and concentrated hydrochloric acid (20 ml). The reaction flask was immediately flushed with nitrogen and plunged into a preheated (140°C) oil bath. With vigorous stirring the reaction mixture was heated at reflux for 65 hrs., cooled to room temperature, diluted with 500 ml chloroform, the layers separated, and the aqueous layers again saturated with chloroform. The combined organic layers were extracted with three 150 ml portions of 2 N aqueous potassium hydroxide, and the combined basic aqueous layers back-extracted with one 150 ml portion of ether. Acidification of the basic aqueous layer with ice bath cooling, extraction with three 250 ml portions of chloroform, drying of the combined organic layers over magnesium sulfate, filtration, and removal of the volatiles afforded 6-phenyl-8-chloro-3,4-dihydro-2H-1-benzo[b]pyran-4-carboxylic acid. Filtration of a chloroform solution of the acid through 400 ml of silica gel (EM Reagents, 70-230 mesh) with elution by three liters of chloroform removes a small amount of a a-hydroxy acid impurity. Recrystallization from cyclohexane yielded 0.93 g (38%) of the acid, m.p. 187-188°C.
- Following the procedure of Example 1, 6,7-dichloro-3,4-dihydro-2H-1-benzo[b]thiopyran-4-one (8.0 g), trimethylsilyl cyanide (40 ml) and zinc iodide (0.5 g) were reacted to give 6,7-dichloro-4-cyano-4-trimethylsilyloxy-3,4-dihydro-2H-1-benzo[b]thiopyran. Filtration and chromatography on silica gel (200 ml) eluted by 1:1 chloroform:hexane yielded 7.5 g (66%) of the desired product.
- Following the procedure of Example 2, 6,7-dichloro-4-cyano-4-trimethylsilyloxy-3,4-dihydro-2H-1-benzo[b]thiopyran (7.5 g) and stannous chloride dihydrate (30 g) were reacted in glacial acetic acid (30 ml) and concentrated hydrochloric acid (30 ml) to form 6,7-dichloro-3,4-dihydro-2H-1-benzo[b]thiopyran-4-carboxylic acid.
-
- Following the procedure of Example 1, 6-chloro-8-methyl-3,4-dihydro-2H-1-benzo[b]pyran-4- one (5.0 g), trimethylsilylcyanide (10 ml) and zinc iodide (0.35 g) were reacted to form 6-chloro-8-methyl-4-cyano-4-trimethylsilyloxy-3,4-dihydro-2H-1-benzo[b]pyran. Filtration and chromatography over silica gel (200 ml) eluted with chloroform:hexane (1:1) yielded 3.3 g of product.
- Following the procedure of Example 2, 6-chloro-8-methyl-4-cyano-4-trimethylsilyloxy-3,4-dihydro-2H-1-benzo[b]pyran (3.1 g), and stannous chloride dihydrate (12.0 g) were reacted in glacial acetic acid (25 ml) and concentrated hydrochloric acid (25 ml) to form 6-chloro-8-methyl-3,4-dihydro-2H-1-benzo[b]pyran-4-carboxylic acid. Recrystallization from hexane yielded 1.67 g of product, m.p. 95-96°C.
- Following the procedure of Example 1, 6,8-dichloro-3,4-dihydro-2H-1-benzo[b]pyran-4-one (6.2 g), trimethylsilyl cyanide (20 ml) and zinc iodide (0.41 g) were reacted in ether (20 ml) to form 6,8-dichloro-4-cyano-4-trimethylsilyloxy-3,4-dihydro-2H-1-benzo[b]pyran. Recrystallization from aqueous isopropanol yielded 6.3 g of product, m.p. 84-85°C.
- Following the procedure of Example 2, 6,8-dichloro-4-cyano-4-trimethylsilyloxy-3,4-dihydro-2H-1-benzo[b]pyran (3.0 g) and stannous chloride dihydrate (15.0 g) were reacted in glacial acetic acid (25 ml) and concentrated hydrochloric acid (25 ml) to form 6,8-dichloro-3,4-dihydro-2H-1-benzo[b]pyran-4-carboxylic acid. Recrystallization from cyclohexane yielded 1.33 g of product, m.p. 124.5-126°C.
- Following the procedure of Example 1, 6-fluoro-3,4-dihydro-2H-1-benzo[b]pyran-4-one (3.74 g), trimethylsilyl cyanide (10 ml) and zinc iodide (0.43 g) were reacted to form 6-fluoro-4-cyano-4-tri- methylsilyloxy-3,4-dihydro-2H-1-benzo[b]pyran. Filtration and chromatography on silica gel (150 ml) eluted with chloroform:hexane (1:1) yielded 5.0 g of product.
- Following the procedure of Example 2, 6-fluoro-4-cyano-4-trimethylsilyloxy-3,4-dihydro-2H-1-benzo[b]pyran (4.72 g) and stannous chloride dihydrate (25 g) were reacted in glacial acetic acid (25 ml) and concentrated hydrochloric acid (25 ml) to form 6-fluoro-3,4-dihydro-2H-1-benzo[b]pyran-4-carboxylic acid. Recrystallization from ethyl acetate:cyclohexane yielded 2.60 g of product, m.p. 118-119°C.
- Following the procedure of Example 1, 6-chloro-3.4-dihydro-2H-1-benzo[b]pyran-4-one (5.0 g), trimethylsilyl cyanide (8.0 g) and zinc iodide (0.50 g) were reacted to form 6-chloro-4-cyano-4-tri- methylsilyloxy-3,4-dihydro-2H-1-benzo[b]pyran. Filtration and chromatography over silica gel (80 ml) eluted with chloroform:hexane (1:1) yielded 7.21 g of product, m.p. 72-73°C.
- Following the procedure of Example 2, 6-chloro-4-cyano-4-trimethylsilyloxy-3,4-dihydro-2H-1-benzo[b]pyran (6.0 g) and stannous chloride dihydrate (30 g) were reacted in glacial acetic acid (25 ml) and concentrated hydrochloric acid (25 ml) to form 6-chloro-3,4-dihydro-2H-1-benzo[b]pyran-4-carboxylic acid. Filtration and chromatography over silica gel (300 ml) eluted with chloroform:hexane (1:1) yielded 2.91 g of product, m.p. 90-90.5°C (sublimed).
- Following the procedure of Example 1, 6-chloro-4H-3,4-dihydro-2H-naphtho[1 ,2-b]pyran-4-one (4.13 g), trimethylsilyl cyanide (15 ml) and zinc iodide (0.75 g) were reacted in ether (15 ml) to give 6-chloro-4-cyano-4-trimethylsilyloxy-3,4-dihydro-2H-naphtho[1,2-b]pyran. Filtration and chromatography on silica gel (250 ml) eluted with 1:1 chloroform:hexane yielded 4.7 g of product.
- Followin the procedure of Example 2, 6-chloro-4-cyano-4-trimethylsilyloxy-3,4-dihydro-2H-naphtho[1,2-b]pyran (0.52 g), stannous chloride dihydrate (1.94 g) were reacted in glacial acetic acid (5 ml) and concentrated hydrochloric acid (5 ml) to form 6-chloro-3,4-dihydro-2H-naphtho[1,2-b]pyran-4-carboxylic acid. Recrystallization from ethyl acetate-hexane yielded 0.23 g of product, m.p. 141-142°C.
- 6-Chioro-3,4-dihydro-2H-1-benzo[b]thiopyran-4-one (6.8 g) was combined with trimethylsilyl cyanide (12 ml) and zinc iodide (0.30 g) and stirred at room temperature for 72 hours. The reaction mixture was diluted with diethyl ether, washed with saturated sodium bicarbonate and with saturated brine. After drying over magnesium sulfate the solution was filtered and evaporated to dryness under vacuum to give 6-chloro-4-cyano-4-trimethylsilyloxy-3,4-dihydro-2H-1-benzo[b]thiopyran (6.0 g, 57%) as an oil.
- Following the procedure of Example 2, 6-chloro-4-cyano-4-trimethylsilyloxy-3,4-dihydro-2H-1-benzo[b]thiopyran (5.8 g) was reacted with stannous chloride dihydrate in glacial acetic acid (25 ml) and concentrated hydrochloric acid (25 ml). Recrystallization from benzene:cyclohexane gave 6-chloro-3,4-dihydro-2H-1-benzo[b]thiopyran-4-carboxylic acid (2.59 g), m.p. 153-154°C.
- In a flame dried flask under nitrogen equipped with a mechanical stirrer, trimethyl phosphonoacetate (10.9 g) was added dropwise to a slurry of 50% sodium hydride (2.9 g) in 300 ml freshly dried tetrahydrofuran and stirred at room temperature for 1 hour. A solution of 6-chloro-3,4-dihydro-2H-1-benzo[b]pyran-4-one (10 g) in 100 ml of freshly dried tetrahydrofuran was added dropwise, keeping the temperature below 30°C during the addition. The solution was then heated at reflux for 5 hours and stirred at room temperature for 12 hours. The solution was poured into ice-water, extracted with diethyl ether, washed with water and dried over magnesium sulfate. The solution was treated with activated charcoal and evaporated under vacuum to yield a yellow oil (6.3 g). Chromatography on silica gel (900 ml) eluted with 1:1 hexane:ethyl acetate yielded 6-chloro-3,4-dihydro-2H-1-benzopyran-4-ylidene-acetic acid methyl ester, (1.6 g, 12%), m.p. 113-115°C.
- 6-Chloro-3,4-dihydro-2H-1-benzo[b]pyran-4-ylidene-acetic acid methyl ester (2.0 g) was reduced with hydrogen using a 10% Pd-charcoal catalyst (0.20 g) by stirring at 25°C in ethyl acetate for 4 hours. The reduction product, 6-chloro-3,4-dihydro-2H-1-benzo[b]pyran-4-acetic acid methyl ester (1.0 g), was heated for 3 days at reflux temperature with potassium hydroxide (2.4 g) in 25 ml water. The solution was acidified and extracted with chloroform. Recrystallization from cyclohexane gave 6-chloro-3,4-dihydro-2H-1-benzo[b]pyran-4-acetic acid (650 mg, 60%), m.p. 115-117°C.
- The compounds produced in Examples 2, 4, 6, 8, 10, 12, 14, 16 and 18 were tested for their ability to reduce or inhibit aldose reductase enzyme activity, following the procedure described in United States Patent No. 3,821,383 and based on the procedure of Hayman et. al., Journal of Biological Chemistry, 240, 877 (1965). The substrate employed was partially purified aldose reductase enzyme obtained from calf lens. The results obtained with each compound at a concentration of 1 0-IM are expressed as percent inhibition of enzyme activity.
- The compounds of Examples 10, 12 and 14 were tested for their ability to reduce or inhibit sorbitol accumulation in the sciatic nerve of streptozotocinized (i.e., diabetic) rats by the procedure essentially described in United States Patent No. 3,821,383. In the present study, the amount oi sorbitol accumulation in the sciatic nerves was measured 27 hours after induction of diabetes. The compounds were administered orally at a 25 mg/kg dosage level at 4, 8 and 24 hours following the administration of streptozotocin. The results obtained in this manner are presented below in terms o1 percent inhibition (%) afforded by the test compound as compared to the case where no compound was administered (i.e., the untreated animal where sorbitol levels normally rise from approximately 50-100 mM/g tissue to as high as 400 mM/g tissue in the 27-hour period):
-
Claims (10)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US05/959,023 US4210663A (en) | 1978-11-08 | 1978-11-08 | Halogen substituted benzopyran- and benzothiopyran-4-carboxylic acids |
US959023 | 1978-11-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0011426A1 EP0011426A1 (en) | 1980-05-28 |
EP0011426B1 true EP0011426B1 (en) | 1983-06-22 |
Family
ID=25501572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP79302467A Expired EP0011426B1 (en) | 1978-11-08 | 1979-11-06 | Halogen-substituted benzopyran- and benzothiopyran-4-carboxylic acids, their preparation and pharmaceutical compositions containing the same |
Country Status (16)
Country | Link |
---|---|
US (1) | US4210663A (en) |
EP (1) | EP0011426B1 (en) |
JP (2) | JPS6033433B2 (en) |
KR (1) | KR830001821B1 (en) |
AR (1) | AR223195A1 (en) |
AT (1) | AT366680B (en) |
AU (1) | AU513399B2 (en) |
CA (1) | CA1132584A (en) |
DE (1) | DE2965755D1 (en) |
DK (1) | DK153947C (en) |
ES (1) | ES485798A1 (en) |
FI (1) | FI71139C (en) |
IE (1) | IE49109B1 (en) |
IL (1) | IL58656A (en) |
PT (1) | PT70420A (en) |
YU (1) | YU41675B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0179570A1 (en) * | 1984-09-26 | 1986-04-30 | Pfizer Inc. | Regeneration of 6-fluoro-4-chromanone from 6-fluoro-4-ureidochroman-4-carboxylic acid |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4305955A (en) * | 1980-10-21 | 1981-12-15 | Pfizer Inc. | Carboxylic acid therapeutic agents |
US4486428A (en) * | 1982-03-16 | 1984-12-04 | Pfizer Inc. | Bicyclic benzo fused compounds |
US4537920A (en) * | 1983-08-18 | 1985-08-27 | Ethyl Corporation | 4H-1-benzopyrans and lubricant compositions containing same |
WO1987004344A1 (en) * | 1986-01-17 | 1987-07-30 | Pfizer Inc. | Hydroxyacetic acid derivatives for the treatment of diabetic complications |
DE3737195A1 (en) * | 1987-11-03 | 1989-05-18 | Bayer Ag | CHROME DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICINAL PRODUCTS |
US5039672A (en) * | 1990-04-05 | 1991-08-13 | Pfizer Inc. | Heterocyclic compounds as aldose reductase inhibitors |
JP3210665B2 (en) * | 1990-07-27 | 2001-09-17 | 中外製薬株式会社 | New benzopyran derivatives |
WO1992014439A1 (en) * | 1991-02-18 | 1992-09-03 | Chugai Seiyaku Kabushiki Kaisha | Hair growth stimulant |
US5407897A (en) * | 1993-03-03 | 1995-04-18 | American Cyanamid Company | Method for safening herbicides in crops using substituted benzopyran and tetrahydronaphthalene compounds |
WO1999043315A1 (en) * | 1998-02-25 | 1999-09-02 | Shionogi & Co., Ltd. | Therapeutic agent for complication of diabetes |
US7288279B2 (en) * | 2001-12-21 | 2007-10-30 | Michael Foods Of Delaware, Inc. | Formulated fried egg product |
JP4742215B2 (en) * | 2003-06-23 | 2011-08-10 | Jnc株式会社 | Chroman compound, liquid crystal composition containing the compound, and liquid crystal display device containing the liquid crystal composition |
JP5956920B2 (en) | 2012-12-14 | 2016-07-27 | 株式会社コガネイ | Liquid supply device |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3821383A (en) * | 1972-07-10 | 1974-06-28 | Ayerst Mckenna & Harrison | Compositions for and a method of treating diabetic complications |
-
1978
- 1978-11-08 US US05/959,023 patent/US4210663A/en not_active Expired - Lifetime
-
1979
- 1979-11-05 YU YU2697/79A patent/YU41675B/en unknown
- 1979-11-06 EP EP79302467A patent/EP0011426B1/en not_active Expired
- 1979-11-06 DE DE7979302467T patent/DE2965755D1/en not_active Expired
- 1979-11-06 AR AR278784A patent/AR223195A1/en active
- 1979-11-06 CA CA339,283A patent/CA1132584A/en not_active Expired
- 1979-11-07 AU AU52582/79A patent/AU513399B2/en not_active Ceased
- 1979-11-07 KR KR1019790003889A patent/KR830001821B1/en active IP Right Grant
- 1979-11-07 JP JP54144280A patent/JPS6033433B2/en not_active Expired
- 1979-11-07 FI FI793487A patent/FI71139C/en not_active IP Right Cessation
- 1979-11-07 PT PT70420A patent/PT70420A/en unknown
- 1979-11-07 IL IL58656A patent/IL58656A/en unknown
- 1979-11-07 ES ES485798A patent/ES485798A1/en not_active Expired
- 1979-11-07 DK DK471079A patent/DK153947C/en not_active IP Right Cessation
- 1979-11-07 IE IE2136/79A patent/IE49109B1/en unknown
- 1979-11-08 AT AT0719279A patent/AT366680B/en not_active IP Right Cessation
-
1980
- 1980-12-15 JP JP17706780A patent/JPS56103176A/en active Granted
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0179570A1 (en) * | 1984-09-26 | 1986-04-30 | Pfizer Inc. | Regeneration of 6-fluoro-4-chromanone from 6-fluoro-4-ureidochroman-4-carboxylic acid |
Also Published As
Publication number | Publication date |
---|---|
KR830001273A (en) | 1983-04-30 |
US4210663A (en) | 1980-07-01 |
FI71139C (en) | 1986-11-24 |
CA1132584A (en) | 1982-09-28 |
YU41675B (en) | 1987-12-31 |
AU5258279A (en) | 1980-05-15 |
JPS6033433B2 (en) | 1985-08-02 |
KR830001821B1 (en) | 1983-09-12 |
FI793487A (en) | 1980-05-09 |
JPS56103176A (en) | 1981-08-18 |
DK153947C (en) | 1989-02-20 |
PT70420A (en) | 1979-12-01 |
DK153947B (en) | 1988-09-26 |
YU269779A (en) | 1983-02-28 |
JPS5585582A (en) | 1980-06-27 |
DE2965755D1 (en) | 1983-07-28 |
AU513399B2 (en) | 1980-11-27 |
IL58656A (en) | 1983-06-15 |
AR223195A1 (en) | 1981-07-31 |
IL58656A0 (en) | 1980-02-29 |
JPS6113716B2 (en) | 1986-04-15 |
ES485798A1 (en) | 1980-10-01 |
IE792136L (en) | 1980-05-08 |
DK471079A (en) | 1980-05-09 |
AT366680B (en) | 1982-04-26 |
EP0011426A1 (en) | 1980-05-28 |
ATA719279A (en) | 1981-09-15 |
FI71139B (en) | 1986-08-14 |
IE49109B1 (en) | 1985-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0011426B1 (en) | Halogen-substituted benzopyran- and benzothiopyran-4-carboxylic acids, their preparation and pharmaceutical compositions containing the same | |
US4117230A (en) | Hydantoin derivatives as therapeutic agents | |
US4130714A (en) | Hydantoin therapeutic agents | |
US4127665A (en) | Thienohydantoin derivatives | |
US4147795A (en) | Hydantoin derivatives as therapeutic agents | |
GB2038315A (en) | Spiro-polycyclic-imidazolidinediones | |
EP0008229B1 (en) | Spiro-furanohydantoin derivatives, process for their preparation and pharmaceutical compositions containing them | |
EP0401981A1 (en) | Pyridazinone deriratives | |
US4209630A (en) | Hydantoin derivatives as therapeutic agents | |
EP0014079B1 (en) | Spiro-quinolylhydantoins, process for their preparation and pharmaceutical compositions thereof | |
JPS6140662B2 (en) | ||
JPS58198467A (en) | Novel prostaglandin derivatives | |
GB2193210A (en) | Glycine derivatives | |
US4282229A (en) | Hydantoin derivatives as therapeutic agents | |
EP0230379B1 (en) | Chroman- and thiochroman-4-acetic acids useful in the treatment of diabetic complications | |
JP4010377B2 (en) | N-benzyldioxothiazolidylbenzamide derivative and process for producing the same | |
US4721719A (en) | Dihydropyridinelactols and their use as medicaments which influence blood sugar | |
US4210756A (en) | Tetrahydroquinoline hydantoins for chronic diabetic complications | |
EP0092386B1 (en) | Hydantoin therapeutic agents | |
US4258054A (en) | Hydantoin derivatives as therapeutic agents | |
US4055654A (en) | 6,8-Di-t-butyl-4-oxo-4H-1-benzopyran-2-carboxylic acid and derivative for the prevention of asthmatic symptoms | |
US4978679A (en) | 6- and/or 7-substituted-1,2,3,4,4A,9B-hexahydro-8-hydroxydibenzofuran-3-ols as inhibitors of leukotriene biosynthesis | |
KR830000329B1 (en) | Process for preparing spiro-oxazolidinedione | |
DE3819999A1 (en) | Novel 6-phenoxymethyl-4-hydroxytetrahydropyran-2-ones and 6-thiophenoxymethyl-4-hydroxytetrahydropyran-2-ones, and the corresponding dihydroxycarboxylic acid derivatives, salts and esters, process for the preparation of these compounds, their use as medicaments, pharmaceutical preparations and novel phenols and thiophenols |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE FR GB IT LU NL SE |
|
17P | Request for examination filed |
Effective date: 19801014 |
|
ITF | It: translation for a ep patent filed |
Owner name: MODIANO & ASSOCIATI S.R.L. |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE FR GB IT LU NL SE |
|
REF | Corresponds to: |
Ref document number: 2965755 Country of ref document: DE Date of ref document: 19830728 |
|
ET | Fr: translation filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 19831103 Year of fee payment: 5 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19831130 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19840925 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19840926 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19840930 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19841025 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19841231 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19871130 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19881106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19881107 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Effective date: 19881130 Ref country code: BE Effective date: 19881130 |
|
BERE | Be: lapsed |
Owner name: PFIZER INC. Effective date: 19881130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19890601 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19890731 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19890901 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
EUG | Se: european patent has lapsed |
Ref document number: 79302467.0 Effective date: 19890726 |